![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.125 | -2.67% | 4.55 | 4.11 | 4.99 | 4.41 | 4.35 | 4.39 | 482,311 | 16:35:06 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.50 | 9.41M |
Date | Subject | Author | Discuss |
---|---|---|---|
01/11/2020 08:51 | Aside from confirming the raise will the next RNS be the peer review (many think it will be in the Lancet) or telling us the home trial recruitment has been completed. Either of those two should be positive and build momentum. The raise RNS can also stabilise us. | ![]() tickboo | |
01/11/2020 07:51 | Agreed, this will start to head north very soon as we near full approval and some more positive results from the phase 3 trial. I think it will certainly be in high demand and on the radar of many governments 🔥🚀 | ![]() strongbuy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions